Related references
Note: Only part of the references are listed.TGFβ-Directed Therapeutics: 2020
Beverly A. Teicher
PHARMACOLOGY & THERAPEUTICS (2021)
Treatment of Myelofibrosis Patients with the TGF-β 1/3 Inhibitor AVID200 (MPN-RC 118) Induces a Profound Effect on Platelet Production
John Mascarenhas et al.
BLOOD (2021)
Phase II study of single-agent nivolumab in patients with myelofibrosis
Iman Abou Dalle et al.
ANNALS OF HEMATOLOGY (2021)
TGF-β1 protein trap AVID200 beneficially affects hematopoiesis and bone marrow fibrosis in myelofibrosis
Lilian Varricchio et al.
JCI INSIGHT (2021)
Regulatory T Cells and Human Disease
Shimon Sakaguchi et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 38 (2020)
Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-β
Alessandra Metelli et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer
Gregoire de Streel et al.
NATURE COMMUNICATIONS (2020)
3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups
Natasha Szuber et al.
MAYO CLINIC PROCEEDINGS (2019)
Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms
Fiorella Schischlik et al.
BLOOD (2019)
Activation of JAK/STAT Signaling in Megakaryocytes Sustains Myeloproliferation In Vivo
Brittany Woods et al.
CLINICAL CANCER RESEARCH (2019)
Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T-cell Immunity Directed against Mutated Calreticulin in Myeloproliferative Neoplasmas
Cansu Cimen Bozkus et al.
CANCER DISCOVERY (2019)
PanglaoDB: a web server for exploration of mouse and human single-cell RNA sequencing data
Oscar Franzen et al.
DATABASE-THE JOURNAL OF BIOLOGICAL DATABASES AND CURATION (2019)
The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy
M. O. Holmstrom et al.
LEUKEMIA (2018)
SHP-1 regulates hematopoietic stem cell quiescence by coordinating TGF-β signaling
Linjia Jiang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2018)
Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms
Alessandro Prestipino et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Structural basis of latent TGF-beta 1 presentation and activation by GARP on human regulatory T cells
Stephanie Lienart et al.
SCIENCE (2018)
Regulatory T cells in cancer immunotherapy
Atsushi Tanaka et al.
CELL RESEARCH (2017)
Cutting Edge: Active TGF-β1 Released from GARP/TGF-β1 Complexes on the Surface of Stimulated Human B Lymphocytes Increases Class-Switch Recombination and Production of IgA
Olivier Dedobbeleer et al.
JOURNAL OF IMMUNOLOGY (2017)
Leptin-receptor-expressing bone marrow stromal cells are myofibroblasts in primary myelofibrosis
Matthew Decker et al.
NATURE CELL BIOLOGY (2017)
Blocking immunosuppression by human Tregs in vivo with antibodies targeting integrin αVβ8
Julie Stockis et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Efficacy of ALK5 inhibition in myelofibrosis
Lanzhu Yue et al.
JCI INSIGHT (2017)
Platelets subvert T cell immunity against cancer via GARP-TGFβ axis
Saleh Rachidi et al.
SCIENCE IMMUNOLOGY (2017)
Preclinical rationale for TGF-β inhibition as a therapeutic target for the treatment of myelofibrosis
Ilaria Ceglia et al.
EXPERIMENTAL HEMATOLOGY (2016)
The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms
M. O. Holmstrom et al.
LEUKEMIA (2016)
The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis
Michael Deininger et al.
BLOOD (2015)
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
Alessandro M. Vannucchi et al.
HAEMATOLOGICA (2015)
Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition
Qiang Jeremy Wen et al.
NATURE MEDICINE (2015)
Monoclonal antibodies against GARP/TGF-β1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo
Julia Cuende et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
JAK-STAT Pathway Activation in Malignant and Nonmalignant Cells Contributes to MPN Pathogenesis and Therapeutic Response
Maria Kleppe et al.
CANCER DISCOVERY (2015)
Oncogenic Drivers in Myeloproliferative Neoplasms: From JAK2 to Calreticulin Mutations
Xavier Cahu et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2015)
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
Alessandro M. Vannucchi et al.
HAEMATOLOGICA (2015)
The Molecular Signatures Database Hallmark Gene Set Collection
Arthur Liberzon et al.
CELL SYSTEMS (2015)
Anti-transforming growth factor-β therapy in patients with myelofibrosis
John Mascarenhas et al.
LEUKEMIA & LYMPHOMA (2014)
Megakaryocytes maintain homeostatic quiescence and promote post-injury regeneration of hematopoietic stem cells
Meng Zhao et al.
NATURE MEDICINE (2014)
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Michael I. Love et al.
GENOME BIOLOGY (2014)
Characterization of the TGF-β1 signaling abnormalities in the Gata1low mouse model of myelofibrosis
Maria Zingariello et al.
BLOOD (2013)
JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα
Salma Hasan et al.
BLOOD (2013)
TGFβ restores hematopoietic homeostasis after myelosuppressive chemotherapy
Fabienne Brenet et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
The relationship of the active and latent forms of TGF-β1 with marrow fibrosis in essential thrombocythemia and primary myelofibrosis
Cesar Cilento Ponce et al.
MEDICAL ONCOLOGY (2012)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Claire Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Nonmyelinating Schwann Cells Maintain Hematopoietic Stem Cell Hibernation in the Bone Marrow Niche
Satoshi Yamazaki et al.
CELL (2011)
Outcome of Transplantation for Myelofibrosis
Karen K. Ballen et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor
Christian Pecquet et al.
BLOOD (2010)
Membrane protein GARP is a receptor for latent TGF-β on the surface of activated human Treg
Julie Stockis et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2009)
Comparison of stable human Treg and Th clones by transcriptional profiling
Julie Stockis et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2009)
Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres
David J. Kuter et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis
Stefan O. Ciurea et al.
BLOOD (2007)
Full restoration of peripheral Foxp3+ regulatory T cell pool by radioresistant host cells in scurfy bone marrow chimeras
Noriko Komatsu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Adenoviral-mediated TGF-beta 1 inhibition in a mouse model of myelofibrosis inhibit bone marrow fibrosis development
Thomas Gastinne et al.
EXPERIMENTAL HEMATOLOGY (2007)
MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia
Yana Pikman et al.
PLOS MEDICINE (2006)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Aberrant expression of transforming growth factor β-1 (TGFβ-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders
O Bock et al.
JOURNAL OF PATHOLOGY (2005)
Global expression profiling of fibroblast responses to transforming growth factor-β1 reveals the induction of inhibitor of differentiation-1 and provides evidence of smooth muscle cell phenotypic switching
RC Chambers et al.
AMERICAN JOURNAL OF PATHOLOGY (2003)
Prominent role of TGF-β1 in thrombopoietin-induced myelofibrosis in mice
H Chagraoui et al.
BLOOD (2002)
Share Paper
